In my previous article, I highlighted the importance of investing in Amicus Therapeutics, a relatively safe stock with high growth potential.
BioMarin Pharmaceutical (BMRN) is another such stock that has ticked all the boxes. The company has a robust commercialized portfolio, a strong R&D pipeline, and a solid balance sheet. The company's third-quarter revenue of $461.1 million was 17.72% higher YoY and ahead of the consensus by $5.31 million. The company's non-GAAP EPS of $0.42 also exceeded the consensus estimate by $0.08.
Previously, I had recommended this stock in July 2019.